Autophagy enhancement has been reported to be useful in preclinical models of diseases: mTOR inhibitors in neurodegenerative diseases [186], tyrosine kinase inhibitors in diabetic nephropathy [187] and neurodegenerative diseases [188,189,190], carbamazepine in α1-antitrypsin deficiency [191], trifluoperazine in Salmonella infection [192] and statins in Mycobacterium tuberculosis infection [193]. Here, MTOR is linked to neurodegenerative disease.